| [1] |
Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer[J]. N Engl J Med, 20 05, 353(25): 2654-66.
|
| [2] |
DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response:crosstalk between adaptive and innate immune cells during breast cancer progression[J]. Breast Cancer Res, 2007, 9(4): 212.
|
| [3] |
Schmidt M, Böhm D, von Törne C, et al. Thehumoral immune system has a key prognostic impact in node-negative breast cancer[J]. Cancer Res, 2008, 68(13): 5405-13.
|
| [4] |
Zitvogel L, Kroemer G. The immune response against dying tumor cells: Avoid disaster, achieve cure[J]. Cell Death Differ, 2008, 15 (1): 1-2.
|
| [5] |
Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy[J]. Immunol Rev, 2007, 220: 47 -59.
|
| [6] |
Apetoh L, Tesniere A, Ghiringhelli F, et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies[J]. Cancer Res, 2008, 68(11): 4026-30.
|
| [7] |
Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy[J]. Nat Rev Immunol, 2008, 8(1): 59-73.
|
| [8] |
Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel[J]. J Clin Oncol, 2002, 20(6): 1456-66.
|
| [9] |
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperativechemotherapy on the outcome of women with operable breast cancer[J]. J Clin Oncol, 1998, 16(8): 2672-85.
|
| [10] |
Black MM, Speer FD, Opler SR. Structural representations of tumor-host relationship in mammary carcinoma: Biologic and prognostic significance[J]. Am J Clin Pathol, 1956, 26(3): 250-65.
|
| [11] |
Denkert C, Loibl S, Noske A. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer[J]. J Clin Oncol, 2010, 28(1): 105-3.
|
| [12] |
Demaria S, Voim MD, Shapiro RL, et al. Development of tumorinfiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy[J].Clin Cancer Res, 2001, 7(10): 3025-30.
|
| [13] |
Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer[J]. Breast Cancer Res Treat, 2012, 13 2(3): 793-805.
|
| [14] |
Feng G, Kang H, Zhang Y, et al. Histopathological changes of breast cancer after neoadjuvant chemotherapy[J]. Shandong Yi Yao, 2009, 49(40), 22-4. [冯根, 康骅, 张雁, 等. 乳腺癌新辅助化 疗前后病理组织学的变化[J]. 山东医药, 2009, 49(40): 22-4.]
|
| [15] |
Rajan R, Esteva FJ, Symmam WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response[J]. Clin Breast Cancer, 2004, 5(3): 235-8.
|
| [16] |
Gong XY, Ding HY. Breast pathology[M]. Beijing: People’s Medical Publishing House, 2009: 506-7. [龚西騟, 丁华野. 乳腺 病理学[M]. 北京: 人民卫生出版社, 2009: 506-7.]
|
| [17] |
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J]. J Clin Oncol, 2008, 26(5): 778-85.
|
| [18] |
Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: Indispensable for therapeutic success?[J]. J Clin Invest, 20 08, 118(6): 1991-2001.
|
| [19] |
Hornychova H, Melichar B, Tomsova M, et al. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma[J]. Cancer Invest, 2008, 26(10): 10 24-31.
|
| [20] |
Ge o rg i a n n o s SN, Re n a u t A, Go o d e AW, e t a l . Th e immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their associatin with prognostic indicators[J]. Surgery, 2003, 13 4(5): 827-34.
|
| [21] |
Leong PP, Mohammad R, Ibrahim N, et al. Phenotyping of lymphocytes expressing regulatory and effect or markers in infiltrating ductal carcinoma of the breast[J]. Immunol Lett, 2006, 10 2(2): 229-36.
|
| [22] |
Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma[J]. Cancer, 1996, 77(7): 1303-10.
|
| [23] |
Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer[J]. Cancer Res, 1998, 58(16): 3491-4.
|
| [24] |
Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up[J]. Cancer, 1977, 40(4): 1365-85.
|
| [25] |
Kuroda H, Tamaru J, Sakamoto G, et al. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast[J]. Virchows Arch, 2005, 446(1): 10-4.
|
| [26] |
Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes[J]. Clin Cancer Res, 2008, 14(16): 5158-65.
|
| [27] |
Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial[J]. J Clin Oncol, 2009, 27(8): 1168-76.
|
| [28] |
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, (8): 2329-34.
|
| [29] |
Parshad R, Kapoor S, Gupta SD, et al. Does famotidine enhance tumor-infiltrating lymphocytes in breast cancer?[J]. Acta Oncol, 20 02, 41(4): 362-5.
|
下载:
